GLP-1 Weight-Loss Boom Linked to Surge in Poison Control Calls, Most Avoidable (opens in new tab)

Covers National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss - Journal of Medical Toxicology

A new study in the Journal of Medical Toxicology traces America's GLP-1 drug boom to an eightfold rise in poison control calls, from 1,500 a year before 2021 to more than 8,000 by 2023, with 64 percent tied to semaglutide alone. Most were avoidable dosing errors, not deliberate misuse.

Read the original article